Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

App aims to help veterans kick the benzodiazepine habit

NCT ID NCT04572750

First seen Jan 28, 2026 · Last updated Jun 22, 2026 · Updated 22 times

Summary

This study tested an app called EMPOWER-ED that provides education and tools to help veterans reduce or stop long-term benzodiazepine use. 170 veterans who had been taking these medications for at least 3 months participated. The app is designed to support self-managed tapering, with the goal of cutting use by 25% or stopping entirely.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BENZODIAZEPINE DEPENDENCE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • VA Palo Alto Health Care System, Palo Alto, CA

    Palo Alto, California, 94304-1207, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

EMPOWER-ED app (behavioral intervention)

What this could lead to

If successful, this app could help many people safely reduce or stop benzodiazepines on their own, lowering risks of dependence and accidents.

What could go wrong

This is a small, completed study in veterans only. The app may not work as well in other groups, and some people may still need medical supervision to quit.

Conditions

The condition(s) this trial relates to.

anxiety disorder insomnia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.